AI-developed drug will be in trials by year-end, says Google’s Hassabis
Isomorphic was spun out of Google’s AI research arm Google DeepMind in 2021, but remains a wholly owned subsidiary of its parent company, Alphabet. The start-up’s potential has attracted big pharmaceutical partners, which are keen to lower expenses and boost efficiency of the costly drug development process.
Google-backed, AI-developed drugs are headed to trial by 2026, DeepMind CEO says
Drugs developed by Alphabet’s drug discovery subsidiary and designed by artificial intelligence are expected to head to trial by the end of the year, according to a Google (GOOGL) executive.
Trials of drugs developed with AI could begin this year, Google DeepMind CEO says
The CEO of Google Mind has suggested clinical trials of the first drugs designed with the help of AI could begin this year.
DeepMind’s Hassabis Sees AI-Designed Drug Trials This Year
Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive officer.
DeepMind expects clinical trials for AI-designed drugs this year
Google DeepMind spinoff Isomorphic Labs expects research of drugs it designed using artificial intelligence will begin this year, according to its Nobel Prize-winning chief executive officer. “We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Google's DeepMind eyes clinical trials for AI-designed drugs in 2025 - report
Google's DeepMind spinoff Isomorphic Labs expects clinical trial of drugs it designed using AI to start this year, Bloomberg News reported, citing the company's CEO Demis Hassabis. "We'll hopefully have some AI-designed drugs in clinical trials by the end of the year,
Alphabet Inc. (GOOGL)’s Isomorphic Labs to Begin Clinical Trials for AI-Designed Drugs, Targeting Faster Drug Discovery
We recently compiled a list of the 10 AI News You Should Not Miss. In this article, we are going to take a look at where ...
Wall Street Lunch: AI-Designed Drugs Expected To See Trials This Year
Google's DeepMind spinoff Isomorphic Labs expects clinical trials of drugs designed using AI to start late this year.
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
The Next Web2d
Europe accelerates AI drug discovery as DeepMind spinoff targets trials this year
Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups ...
pharmaphorum1y
Isomorphic signs up Lilly, Novartis for $3bn AI drug hunt
Alphabet’s artificial intelligence start-up Isomorphic Labs has made a splash at the start of the JP Morgan Healthcare conference this week, announcing its first pharma partnerships with Eli ...
Fast Company6mon
Isomorphic Labs
DeepMind’s new AlphaFold 3 expands to DNA, RNA modeling Google DeepMind expands its AlphaFold AI system to model how proteins interact with other cell structures including DNA and RNA.
C&EN8d
Q&A: What Novartis’s biomedical research head sees in AI
The pharma giant is partnering with software firms to imagine new drugs, find targets, and design clinical trials ...
Forbes4mon
Google DeepMind And Isomorphic Labs Are Making Rapid Progress In Biology And Drug Discovery
Among the most important aspects of this story is AlphaFold, the artificial intelligence and foundation model platform developed by Google DeepMind and Isomorphic Labs, both Alphabet companies.